Leerink Swann Maintains an 'Outperform' on Allergen (AGN); FDA Approval of Restylane for Lip Augmentation May Expand Filler Market
Go back to Leerink Swann Maintains an 'Outperform' on Allergen (AGN); FDA Approval of Restylane for Lip Augmentation May Expand Filler Market| Allergan Inc (NYSE: AGN) | Delayed: 193.02 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $193.02 | 52 Week High | $322.68 | |||
| Open | $15.33 | 52 Week Low | $186.34 | |||
| Day High | $193.02 | P/E | 45.96 | |||
| Day Low | $193.02 | EPS | $4.20 | |||
| Volume | 43,377 | |||||
| Medicis Pharmaceutical Corp. (NASDAQ: MRX) | Delayed: 71.06 -1.3 (1.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $72.36 | 52 Week High | $44.00 | |||
| Open | $72.37 | 52 Week Low | $30.30 | |||
| Day High | $72.37 | P/E | 102.99 | |||
| Day Low | $69.43 | EPS | $0.69 | |||
| Volume | 815,365 | |||||
